# Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

> **NCT02036424** · PHASE4 · COMPLETED · sponsor: **Raj K. Maturi, MD** · enrollment: 45 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Ozurdex
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02036424
- **Lead sponsor:** Raj K. Maturi, MD
- **Sponsor class:** INDIV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02036424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02036424, "Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02036424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*